LUCIRA HEALTH INC (LHDX) Fundamental Analysis & Valuation

NASDAQ:LHDX • US54948U1051

Current stock price

0.4523 USD
-0.11 (-19.23%)
At close:
0.405 USD
-0.05 (-10.46%)
After Hours:

This LHDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LHDX Profitability Analysis

1.1 Basic Checks

  • In the past year LHDX has reported negative net income.
  • In the past year LHDX has reported a negative cash flow from operations.
LHDX Yearly Net Income VS EBIT VS OCF VS FCFLHDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 -20M -40M -60M -80M -100M

1.2 Ratios

  • LHDX has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LHDX Yearly ROA, ROE, ROICLHDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 0 200 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LHDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LHDX Yearly Profit, Operating, Gross MarginsLHDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. LHDX Health Analysis

2.1 Basic Checks

  • LHDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • LHDX has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for LHDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LHDX Yearly Shares OutstandingLHDX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 10M 20M 30M
LHDX Yearly Total Debt VS Total AssetsLHDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 50M 100M 150M 200M

2.2 Solvency

  • LHDX has an Altman-Z score of -2.89. This is a bad value and indicates that LHDX is not financially healthy and even has some risk of bankruptcy.
  • LHDX's Altman-Z score of -2.89 is on the low side compared to the rest of the industry. LHDX is outperformed by 67.76% of its industry peers.
  • A Debt/Equity ratio of 0.48 indicates that LHDX is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.48, LHDX is not doing good in the industry: 67.76% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z -2.89
ROIC/WACCN/A
WACC8.96%
LHDX Yearly LT Debt VS Equity VS FCFLHDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 100M -100M

2.3 Liquidity

  • A Current Ratio of 1.46 indicates that LHDX should not have too much problems paying its short term obligations.
  • The Current ratio of LHDX (1.46) is worse than 84.11% of its industry peers.
  • LHDX has a Quick Ratio of 1.46. This is a bad value and indicates that LHDX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • LHDX has a Quick ratio of 0.79. This is amonst the worse of the industry: LHDX underperforms 87.85% of its industry peers.
Industry RankSector Rank
Current Ratio 1.46
Quick Ratio 0.79
LHDX Yearly Current Assets VS Current LiabilitesLHDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. LHDX Growth Analysis

3.1 Past

  • LHDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -84.60%.
  • The Revenue has grown by 564.27% in the past year. This is a very strong growth!
EPS 1Y (TTM)-84.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-570.21%
Revenue 1Y (TTM)564.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%129.63%

3.2 Future

  • LHDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.35% yearly.
  • The Revenue is expected to grow by 30.23% on average over the next years. This is a very strong growth
EPS Next Y83%
EPS Next 2Y25.35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year201.55%
Revenue Next 2Y30.23%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

LHDX Yearly Revenue VS EstimatesLHDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 50M 100M 150M 200M
LHDX Yearly EPS VS EstimatesLHDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. LHDX Valuation Analysis

4.1 Price/Earnings Ratio

  • LHDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LHDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LHDX Price Earnings VS Forward Price EarningsLHDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LHDX Per share dataLHDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • LHDX's earnings are expected to grow with 25.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.35%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LHDX Dividend Analysis

5.1 Amount

  • LHDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

LHDX Fundamentals: All Metrics, Ratios and Statistics

LUCIRA HEALTH INC

NASDAQ:LHDX (3/3/2023, 8:01:46 PM)

After market: 0.405 -0.05 (-10.46%)

0.4523

-0.11 (-19.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-09
Earnings (Next)05-10
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners13.86%
Ins Owner Change0%
Market Cap18.36M
Revenue(TTM)212.13M
Net Income(TTM)-143.28M
Analysts43.33
Price Target0.77 (70.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-367.7%
Min EPS beat(2)-705.63%
Max EPS beat(2)-29.76%
EPS beat(4)2
Avg EPS beat(4)-10.85%
Min EPS beat(4)-705.63%
Max EPS beat(4)590.2%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-5.94%
Min Revenue beat(2)-14.7%
Max Revenue beat(2)2.82%
Revenue beat(4)3
Avg Revenue beat(4)9.87%
Min Revenue beat(4)-14.7%
Max Revenue beat(4)47.42%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-280.95%
EPS NY rev (1m)0%
EPS NY rev (3m)43.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-52.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.09
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB 0.3
EV/EBITDA N/A
EPS(TTM)-3.19
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-2.67
FCFYN/A
OCF(TTM)-2.03
OCFYN/A
SpS5.23
BVpS1.5
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover1.12
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 398.51%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.46
Quick Ratio 0.79
Altman-Z -2.89
F-Score2
WACC8.96%
ROIC/WACCN/A
Cap/Depr(3y)2388.56%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-84.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-570.21%
EPS Next Y83%
EPS Next 2Y25.35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)564.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%129.63%
Revenue Next Year201.55%
Revenue Next 2Y30.23%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-104.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-193.12%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-352.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-347.8%
OCF growth 3YN/A
OCF growth 5YN/A

LUCIRA HEALTH INC / LHDX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for LUCIRA HEALTH INC?

ChartMill assigns a fundamental rating of 2 / 10 to LHDX.


What is the valuation status for LHDX stock?

ChartMill assigns a valuation rating of 3 / 10 to LUCIRA HEALTH INC (LHDX). This can be considered as Overvalued.


How profitable is LUCIRA HEALTH INC (LHDX) stock?

LUCIRA HEALTH INC (LHDX) has a profitability rating of 0 / 10.